XML 24 R37.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Revenue Recognition - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | ---
Sep. 03, 2014 | Jan. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Mar. 31, 2014 | Sep. 30, 2015 | Sep. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | $ 2,115,000 |
Non-refundable up-front payment |  |  |  |  |  |  | 2,000,000 |
Payment to be received upon signing of agreement |  |  |  |  |  |  | 126,000 |
Revenue recognized under revenue recognition, up front payment |  |  |  |  |  | $ 2,000,000 |  |
Royalty and other revenue |  |  |  |  | $ 126,000 |  |  | $ 2,117,000
Technology Transfer |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 0 |  |
Estimated selling price |  |  |  | $ 300,000 |  |  | 300,000 |
Consideration allocated to transaction |  |  |  | 11,000 |  |  | 11,000 |
Royalty and other revenue |  |  | $ 126,000 |  |  |  |  |
Clinical Development |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  | 60,000,000 |
Potential milestone payments to be received |  |  |  | 60,000,000 |  |  | 60,000,000 |
Initial Commercial Sales |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Potential milestone payments to be received |  |  |  | 100,000,000 |  |  | 100,000,000 |
BioMarin Pharmaceutical, Inc. | Asset Purchase Agreement |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Upfront payment received under purchase agreement |  | $ 2,000,000 |  |  |  |  |  |
Potential milestone payments to be received |  |  |  | 160,000,000 |  |  | 160,000,000 |
Provision for refund |  |  |  |  |  |  | 0 |
Revenue recognized |  |  |  | $ 0 |  |  | $ 0 | $ 2,100,000
BioMarin Pharmaceutical, Inc. | Clinical Development | Asset Purchase Agreement |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Percentage relate to clinical development from Milestone payment |  |  |  |  |  |  | 37.00% |
BioMarin Pharmaceutical, Inc. | Initial Commercial Sales | Asset Purchase Agreement |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Percentage relate to clinical development from Milestone payment |  |  |  |  |  |  | 63.00% |
BioMarin Pharmaceutical, Inc. | Technology Transfer Payments | Asset Purchase Agreement |  |  |  |  |  |  |  |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |  |  |  |  |  |  |  |
Milestone Payment | $ 126,000 |  |  |  |  |  |  |

X
- Definition Amount To Be Received Upon Completion Of Transfer + References No definition available. + Details
Name: | rgen_AmountToBeReceivedUponCompletionOfTransfer
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consideration Allocated To Transaction Rights + References No definition available. + Details
Name: | rgen_ConsiderationAllocatedToTransactionRights
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Long Lived Assets Held for sale, Estimated Selling Cost + References No definition available. + Details
Name: | rgen_LongLivedAssetsHeldForSaleEstimatedSellingCost
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance + References No definition available. + Details
Name: | rgen_NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable Upfront Cash Payment Under Collaborations Agreement + References No definition available. + Details
Name: | rgen_NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Future Milestone Payments + References No definition available. + Details
Name: | rgen_PercentageOfFutureMilestonePayments
Namespace Prefix: | rgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Additional Milestone Payments Associated With Potential Regulatory Approvals + References No definition available. + Details
Name: | rgen_PotentialAdditionalMilestonePaymentsAssociatedWithPotentialRegulatoryApprovals
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Provision For Wholesale Refunds + References No definition available. + Details
Name: | rgen_ProvisionForWholesaleRefunds
Namespace Prefix: | rgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rgen_TechnologyTransferMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_ClinicalResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_FirstCommercialSaleMilestoneEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=rgen_BiomarinPharmaceuticalIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=rgen_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rgen_TechnologyTransferPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |